{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:53:02Z","timestamp":1777949582197,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03619-0","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:48:55Z","timestamp":1774428535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B and T cells in lung tissue are associated with smoking and forced vital capacity in idiopathic pulmonary fibrosis and familial pulmonary fibrosis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2564-1420","authenticated-orcid":false,"given":"Hanna","family":"Jaula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervi","family":"Kreus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Lepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Lappi-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"V\u00e4h\u00e4nikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terttu","family":"Harju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Kaarteenaho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"5","key":"3619_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368. Available from: 2024 Jan 18. https:\/\/pubmed.ncbi.nlm.nih.gov\/30168753\/. Cited 2024 Jan 18.","journal-title":"Am J Respir Crit Care Med"},{"key":"3619_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2021","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2021;17:515\u201346.","journal-title":"Annu Rev Pathol"},{"issue":"17","key":"3619_CR3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","volume":"83","author":"F Bonella","year":"2023","unstructured":"Bonella F, Spagnolo P, Ryerson C. Current. and future treatment landscape for idiopathic pulmonary fibrosis. Drugs. 2023;83(17):1581\u201393. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37882943\/. Cited 2025 Feb 10.","journal-title":"Drugs"},{"issue":"2","key":"3619_CR4","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26177183\/. Cited 2025 Feb 10.","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"3619_CR5","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.cell.2024.05.015","volume":"187","author":"M Kamiya","year":"2024","unstructured":"Kamiya M, Carter H, Espindola MS, Doyle TJ, Lee JS, Merriam LT et al Immune mechanisms in fibrotic interstitial lung disease. Cell. 2024;187(14):3506\u201330. Available from: https:\/\/doi.org\/10.1016\/j.cell.2024.05.015.","journal-title":"Cell"},{"key":"3619_CR6","doi-asserted-by":"crossref","unstructured":"Borie R, Kannengiesser C, Antoniou K, Bonella F, Crestani B, Fabre A et al. European respiratory society statement on familial pulmonary fibrosis. Eur Respir J. 2023;61(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36549714\/. Cited 2023 Sep 30.","DOI":"10.1183\/13993003.01383-2022"},{"issue":"1","key":"3619_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-024-02864-5","volume":"25","author":"H Jaula","year":"2024","unstructured":"Jaula H, Mattila L, Lappi-Blanco E, Salonen J, V\u00e4h\u00e4nikkil\u00e4 H, Ahvenj\u00e4rvi L et al Clinical, radiological and histopathological features of patients with familial pulmonary fibrosis. Respir Res. 2024;25(1):1\u201313. Available from: https:\/\/doi.org\/10.1186\/s12931-024-02864-5.","journal-title":"Respir Res"},{"issue":"5","key":"3619_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.chest.2021.01.026","volume":"159","author":"CC Cutting","year":"2021","unstructured":"Cutting CC, Bowman WS, Dao N, Pugashetti JV, Garcia CK, Oldham JM et al. Family history of pulmonary fibrosis predicts worse survival in patients with interstitial lung disease. Chest. 2021;159(5):1913. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8173755\/. Cited 2023 Oct 13.","journal-title":"Chest"},{"key":"3619_CR9","doi-asserted-by":"crossref","unstructured":"Zhang D, Newton CA, Wang B, Povysil G, Noth I, Martinez FJ. et al. Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis. Eur Respir J. 2022;60(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36028256\/. Cited 2023 Sep 27.","DOI":"10.1183\/13993003.00577-2022"},{"key":"3619_CR10","doi-asserted-by":"publisher","unstructured":"Ruiz A, Flores-Gonzalez J, Buendia-Roldan I, Chavez-Galan L. Telomere shortening and its association with cell dysfunction in lung diseases. Int J Mol Sci. 2022;23(1). https:\/\/doi.org\/10.3390\/ijms23010425.","DOI":"10.3390\/ijms23010425"},{"key":"3619_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"P von der Heukels","year":"2019","unstructured":"Heukels P, Moor CC, von der Th\u00fcsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79\u201391. Available from: http:\/\/www.resmedjournal.com\/article\/S0954611119300071\/fulltext. Cited 2025 Feb 6.","journal-title":"Respir Med"},{"key":"3619_CR12","doi-asserted-by":"publisher","unstructured":"Parra ER, Kairalla RA, Ribeiro De Carvalho CR, Eher E, Capelozzi VL. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. 2007;74(2):159\u201369. https:\/\/doi.org\/10.1159\/000097133.","DOI":"10.1159\/000097133"},{"issue":"1","key":"3619_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JIR.S40673","volume":"6","author":"NW Todd","year":"2013","unstructured":"Todd NW, Scheraga RG, Galvin JR, Iacono AT, James Britt E, Luzina IG et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res. 2013;6(1):63\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23576879\/. Cited 2025 Feb 13.","journal-title":"J Inflamm Res"},{"key":"3619_CR14","doi-asserted-by":"publisher","unstructured":"Cocconcelli E, Balestro E, Turato G, Fiorent\u00f9 G, Bazzan E, Biondini D et al. Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1437767.","DOI":"10.3389\/fimmu.2024.1437767"},{"key":"3619_CR15","doi-asserted-by":"publisher","unstructured":"Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. american society for clinical investigation. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI143226.","DOI":"10.1172\/JCI143226"},{"issue":"6","key":"3619_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1164\/rccm.201001-0076OC","volume":"183","author":"C Taille","year":"2011","unstructured":"Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(6):759\u201366. Available from: https:\/\/doi.org\/10.1164\/rccm.201001-0076OC. Cited 2025 Jun 24.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3619_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI116015","volume":"90","author":"AE Postlethwaite","year":"1992","unstructured":"Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest. 1992;90(4):1479\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1401080\/. Cited 2026 Feb 11.","journal-title":"J Clin Invest"},{"issue":"3","key":"3619_CR18","doi-asserted-by":"publisher","first-page":"L487","DOI":"10.1152\/ajplung.00301.2018","volume":"316","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang D, Wang L, Wang S, Roden AC, Zhao H et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A\/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2019;316(3):L487\u201397. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30604628\/. Cited 2026 Feb 11.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3619_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pupt.2017.05.007","volume":"45","author":"G Passalacqua","year":"2017","unstructured":"Passalacqua G, Mincarini M, Colombo D, Troisi G, Ferrari M, Bagnasco D et al. IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulm Pharmacol Ther. 2017;45:95\u2013100. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28501346\/. Cited 2026 Feb 11.","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"3619_CR20","first-page":"95","volume":"59","author":"Y Xu","year":"2023","unstructured":"Xu Y, Lan P, Wang T. The role of immune cells in the pathogenesis of idiopathic pulmonary fibrosis. Medicina (B Aires). 2023;59(11). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10672798\/. Cited 2024 Jan 17.","journal-title":"Medicina (B Aires)"},{"issue":"5","key":"3619_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1378\/chest.101.5.1326","volume":"101","author":"AS Narayanan","year":"1992","unstructured":"Narayanan AS, Whithey J, Souza A, Raghu G. Effect of \u03b3-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest. 1992;101(5):1326\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1582292\/. Cited 2026 Feb 11.","journal-title":"Chest"},{"key":"3619_CR22","unstructured":"Evans J. Straightforward statistics for the behavioral sciences. 1996. Available from: https:\/\/psycnet.apa.org\/record\/1995-98499-000. Cited 2026 Feb 15."},{"key":"3619_CR23","doi-asserted-by":"publisher","unstructured":"Daniil Z, Kitsanta P, Kapotsis G, Mathioudaki M, Kollintza A, Karatza M et al. CD8\u2009+\u2009T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis. Respir Res. 2005;6(1). Available from: Cited 2025 May 19. https:\/\/doi.org\/10.1186\/1465-9921-6-81.","DOI":"10.1186\/1465-9921-6-81"},{"issue":"3","key":"3619_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/modpathol.2011.166","volume":"25","author":"GJ Nuovo","year":"2012","unstructured":"Nuovo GJ, Hagood JS, Magro CM, Chin N, Kapil R, Davis L et al. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol. 2012;25(3):416\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22037258\/. Cited 2024 Mar 11.","journal-title":"Mod Pathol"},{"key":"3619_CR25","doi-asserted-by":"publisher","first-page":"736485","DOI":"10.3389\/fmed.2021.736485","volume":"8","author":"AA van Batenburg","year":"2021","unstructured":"van Batenburg AA, van Oosterhout MFM, Knoppert SN, Kazemier KM, van der Vis JJ, Grutters JC et al. The extent of inflammatory cell infiltrate and fibrosis in lungs of telomere- and surfactant-related familial pulmonary fibrosi. Front Med (Lausanne). 2021;8:736485. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8497799\/. Cited 2024 Mar 11.","journal-title":"Front Med (Lausanne)"},{"issue":"19","key":"3619_CR26","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1182\/bloodadvances.2025015976","volume":"9","author":"WR Gomes","year":"2025","unstructured":"Gomes WR, Hama S, Napolitani G, Tan A, Catto LFB, Donaires FS, et al. Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders. Blood Adv. 2025;9(19):4790\u2013805.","journal-title":"Blood Adv"},{"issue":"5","key":"3619_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/ATVBAHA.118.312338","volume":"39","author":"KM Pedersen","year":"2019","unstructured":"Pedersen KM, \u00c7olak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Smoking and Increased White and Red Blood Cells: A Mendelian Randomization Approach in the Copenhagen General Population Study. Arterioscler Thromb Vasc Biol. 2019;39(5):965\u201377. Available from: https:\/\/doi.org\/10.1161\/ATVBAHA.118.312338. Cited 2025 Jun 15.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3619_CR28","doi-asserted-by":"publisher","unstructured":"Jaula H, Lepp\u00e4nen J, Mattila L, Ahvenj\u00e4rvi L, Nurkkala E, Lampela H et al. Bronchoalveolar lavage cell differential count is associated with survival and radiological UIP pattern in familial pulmonary fibrosis. BMC Pulm Med. 2026J an 27;26(1):84. Available from: Cited 2026 Feb 17. https:\/\/doi.org\/10.1186\/s12890-026-04119-z.","DOI":"10.1186\/s12890-026-04119-z"},{"key":"3619_CR29","doi-asserted-by":"publisher","unstructured":"Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G et al. Immune inflammation and disease progression in idiopathic pulmonary fibrosis. PLoS One. 2016;11(5). Available from: Cited 2025 May 16. https:\/\/doi.org\/10.1371\/journal.pone.0154516.","DOI":"10.1371\/journal.pone.0154516"},{"key":"3619_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.envres.2017.06.038","volume":"158","author":"Y Astuti","year":"2017","unstructured":"Astuti Y, Wardhana A, Watkins J, Wulaningsih W. Cigarette smoking and telomere length: A systematic review of 84 studies and meta-analysis. Environ Res. 2017;158:480\u20139. Available from: https:\/\/doi.org\/10.1016\/j.envres.2017.06.038. Cited 2022 Feb 11.","journal-title":"Environ Res"},{"issue":"1","key":"3619_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cellimm.2013.04.005","volume":"282","author":"CP Hernandez","year":"2013","unstructured":"Hernandez CP, Morrow K, Velasco C, Wyczechowska DD, Naura AS, Rodriguez PC. Effects of cigarette smoke extract on primary activated T cells. Cell Immunol. 2013;282(1):38\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23665673\/. Cited 2026 Feb 16.","journal-title":"Cell Immunol"},{"key":"3619_CR32","doi-asserted-by":"publisher","unstructured":"K\u00e4rkk\u00e4inen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18. https:\/\/doi.org\/10.1186\/s12931-017-0642-6.","DOI":"10.1186\/s12931-017-0642-6"},{"key":"3619_CR33","doi-asserted-by":"publisher","unstructured":"Mononen M, Saari E, Hasala H, Kettunen HP, Suoranta S, Nurmi H et al. Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases. BMC Pulm Med. 2022;22(1). Available from: Cited 2025 Jun 15. https:\/\/doi.org\/10.1186\/s12890-022-02105-9.","DOI":"10.1186\/s12890-022-02105-9"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03619-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:10:47Z","timestamp":1777860647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03619-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3619"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03619-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the study, the need to obtain informed consent was waived, in accordance with Finnish legislation. The study protocol was approved by the Ethical Committee of the Northern Ostrobothnia Hospital District (64\/2001, amendments 68\/2005, 2\/2008, 2\/2015 and 115\/2018). Paraffin-embedded tissue samples were approved for research use by the National Supervisory Authority for Welfare and Health (V\/25054 and V\/25090\/2019). The study was conducted in compliance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appilicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HJ has received congress fees and travel costs from Chiesi, Mediq and Sanofi and lecture fees from AstraZeneca outside of the submitted work. JL reports congress fees and travel costs from Sanofi and GlaxoSmithKline, outside of the submitted work. RK has received lecture fees from Boehringer-Ingelheim and advisory board fees from MSD and Boehringer-Ingelheim and congress costs from Orion Pharma outside of the submitted work. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}